Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    In-Person

    What is this Study about?

    The goal of this study is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in the brain in individuals who are at an increased risk for developing Alzheimer's Disease. Only participants who show the abnormal brain signaling on a functional MRI (fMRI) scan of the brain will be enrolled in the study. Enrolled participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill). The study involves cognitive testing, genetic testing, bloodwork, ECGs, questionnaires and several brain imaging scans.

    Eligibility Criteria

    • Are between 55-85 years of age

    • Have a parent or sibling with Alzheimer’s disease or with dementia that may be due to Alzheimer’s disease (even if not diagnosed as such)

    • Feel your memory is getting worse

    • Get normal scores on tests of thinking and memory (will be done as part of the study)

    • Are able to undergo brain MRI scans

    • Have a study partner (friend or family member) willing to answer questionnaires about you

    • Show increased brain signaling during the screening fMRI scan (Note: We anticipate that most people who sign up for the study will NOT show the increased brain activity levels required to qualify for the study treatment)

    Recruitment End Date

  • Observational Study
    Online

    What is this Study about?

    This study looks at how an at-home nature-based virtual reality (VR) program may help people living with Alzheimer’s Disease manage behavioural and psychological symptoms of dementia (BPSD), such as depression. Caregivers and/or study partners will have the option of taking part in the study and providing feedback regarding the VR intervention. This project will explore how virtual reality can be used as a non-pharmacological approach to prolong aging in place for individuals with BPSD, as BPSD contributes to rates of institutionalization.

    Eligibility Criteria

    • Are 50 years or older
    • Have been diagnosed with mild to early-moderate Alzheimer's disease (including mixed dementia)
    • Are medically stable and able to take part safely
    • Experience mild to moderate depressive symptoms
    • Feel comfortable using basic technology, such as a tablet or headset
    • Have access to Wi-Fi and a smart device (such as a phone or tablet) for online sessions and study apps
    • Have someone available to be present during all study sessions

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).

    The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

    Eligibility Criteria

    Male or female participants aged 55 to 90 years of age
    Must have a study partner
    Presence of psychotic symptoms for at least 2 months before Screening.

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

  • Clinical Trial
    In-Person

    What is this Study about?

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 55 years of age to 90.
    Must have a study partner
    History of agitation due to AD.

    Recruitment End Date

  • Clinical Trial
    UHN - TO Western - Dr. Tartaglia

    What is this Study about?

    The purpose of this study is to:Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) and Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    Eligibility Criteria

    Male or female participants aged 40 to 80 years of age
    Has mild cognitive impairment (MCI) or dementia due to AD

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Older adults are at greater risk for experiencing a reduction in cognitive and physical function. It is imperative that we identify health behaviors and non-pharmacological (i.e., non-medication) interventions to mitigate these declines. One promising lifestyle intervention to prevent or delay the onset of such declines is exercise, which has been found to improve cognitive function (mental abilities used to perform simple and complex tasks), physical function (muscle mass, bone density) and brain health (structure and function). There is also research demonstrating that creatine, a naturally occurring compound in the body known to decrease with age, can increase muscle mass and bone density in older adults when supplemented. However, it is unclear what effects creatine may have on cognition and brain health in older adults. Thus, our project will investigate the effects of creatine supplementation on cognition and brain health in older adults when combined with different types of exercise. Given the safety, accessibility and known reduction in creatine levels with age, examining how creatine supplementation may benefit older adults is well worth investigating.

    Eligibility Criteria

    To be eligible to participate in this study you must:

    • be 60 years of age or older

    • be living independently in the community

    • have normal or corrected-to-normal vision and hearing

    • read, write, and speak English fluently

    • have feelings of memory decline in the past 5 years

    • be able to exercise at a moderate pace for 60 minutes 3x/week receive clearance from a medical doctor (once deemed eligible) to participate in an exercise program

    You are ineligible to participate in this study if you:

    • cannot partake or commit to exercise training 3x/week for 26 weeks or have regularly engaged in exercise (more than once per week) over the past 3 months

    • cannot partake or commit to consuming a daily supplement for 26 weeks or consumed nutritional supplements containing creatine monohydrate over the past 3 months

    • have a known allergy to creatine monohydrate or dextrose (glucose, D-glucose)

    • have been diagnosed with a neurological disorder (e.g., Alzheimer’s disease, Parkinson’s disease)

    • have pre-existing kidney disease, heart disease, or liver abnormalities

    • have one or more uncontrolled chronic or psychiatric conditions (e.g., hypertension, diabetes, depression, anxiety)

    • are taking medication that may impact kidney function (e.g., non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen)

    • are ineligible or uncomfortable with blood sampling.

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    McMaster University is conducting a study on the effects of brain stimulation in individuals aged 50 and older with dementia or memory loss. The research focuses on using repetitive transcranial magnetic stimulation (rTMS), a noninvasive technique that delivers magnetic pulses to the brain, to enhance cognitive function and balance. The goal is to extend the positive effects of brain stimulation in improving cognition and balance in individuals with dementia.

    Eligibility Criteria

    1.) Diagnosed with Dementia and/or memory loss by a clinician

    2.) Exhibit adequate oral communication skills and cognitive function

    3.) Walk or stand with or without personnel or assistive devices

    4.) Individuals must be greater than or equal to 50 years of age

    Recruitment End Date

  • Observational Study
    In-Person

    What is this Study about?

    Compass-ND is a research study designed to assess individuals with different sorts of cognitive and movement changes seen in older adults. We will look at the usefulness of imaging studies, clinical assessments and biomarker tests, together with measurements of memory, thinking and daily functioning, for distinguishing these changes from each other and from healthy aging.

    Eligibility Criteria

    - are between the ages 60-90

    - have up to grade 12 education

    - have an individual (spouse, friend, or relative), called a “study partner,” who is willing to:

    - Accompany you to the study visits

    - Communicate to the study staff of changes in your health status over the period of this study

    Recruitment End Date